Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

Article Details

Citation

Copy to clipboard

Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

J Hypertens. 2017 Sep;35(9):1758-1767. doi: 10.1097/HJH.0000000000001412.

PubMed ID

28509722 [ View in PubMed

]

Abstract

: To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. beta-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on partially overlapping mechanisms of action and limited evidence. Recently, the single-pill combination (SPC) of nebivolol (Neb) 5 mg - a vasodilatory beta1-selective antagonist/beta3 agonist - and valsartan 80 mg, an angiotensin II receptor blocker, was US Food and Drug Administration-approved for hypertension. Pharmacological profiles of Neb and valsartan, alone and combined, are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N = 4161) demonstrated greater blood pressure-reducing efficacy for Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers substudy (N = 805), Neb/valsartan SPCs prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest SPC dose vs. valsartan 320 mg/day. This review summarizes preclinical and clinical evidence supporting Neb/valsartan as an efficacious and well tolerated combination treatment for hypertension.

DrugBank Data that Cites this Article

Drugs

Nebivolol

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Nebivolol	Beta-3 adrenergic receptor	Protein	Humans	Unknown	Agonist	Details